This writer digs into the CRISPR gene-editing space, asking whether one particular penny stock is worth taking a punt on in his ISA. The post Could buying this gene-editing penny stock at $1 make me ...
ROCHESTER, N.Y. – Researchers at Golisano Children’s Hospital have received a multi-million-dollar grant to lead a ...
In a study published in Nature Communications, researchers at the Beijing Institute of Stem Cells and Regeneration (BISCRM) ...
Spread the love Table of Contents Introduction Methodology Top 10 Biotech Giants Rising Stars (11-25) Innovators and ...
Recent headlines in the U.K. lauded the approval of a new sickle cell cure using gene-editing technology. Columnist Mary ...
Novo Nordisk’s rare disease ‘company within a company’ has an open goal in sickle cell
Novo Nordisk's rare disease unit awaits Phase 3 data for etavopivat in sickle cell disease, aiming for 50% VOC reduction ...
Congress did not reauthorize the rare pediatric disease priority review program at the end of 2024. Advocates say the ripple ...
CRISPR Therapeutics AG ( NASDAQ: CRSP) TD Cowen 45th Annual Healthcare Conference March 3, 2025 10:30 AM ET ...
When Vijay Sankaran was an MD-PhD student at Harvard Medical School in the mid-2000s, one of his first clinical encounters ...
During his visit to the Kingdom of Bahrain, the Director-General of the World Health Organization (WHO), Dr. Tedros Adhanom ...
A new review in Engineering reveals that CRISPR technologies are revolutionizing regenerative medicine. Scientists from ...
Sickle cell disease is a severe ... Recent advances in gene therapy and CRISPR technology have opened new possibilities for treating and potentially curing SCD. Some experimental treatments ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback